Robertson D G, Loewen G, Walsh K M, Dethloff L A, Sigler R S, Dominick M A, Urda E R
Department of Pathology and Experimental Toxicology, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Co., Ann Arbor, Michigan 48106.
Fundam Appl Toxicol. 1993 May;20(4):446-55. doi: 10.1006/faat.1993.1055.
CI-986 (5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)- thione-2-hydroxy-N,N,N-trimethylethanaminium salt) is a novel anti-inflammatory compound classified as a dual inhibitor of cyclooxygenase and 5-lipoxygenase. Studies were undertaken to characterize the preclinical toxicology of the compound. CI-986 was administered to rats for 2 weeks (0, 50, 250, 750, and 1500 mg/kg) or 13 weeks (0, 20, 250, 500, and 1000 mg/kg), dogs for 2 weeks (0, 50, 150, and 500 mg/kg) or 13 weeks (0, 20, 100, and 200 mg/kg), and to monkeys for 2 weeks (0, 50, 250, and 1000 mg/kg). No drug-related deaths resulted. Mild clinical signs of toxicity were noted in rats given doses of 250 mg/kg and above. Drug-related emesis and diarrhea were absent at the low dose in the dog and monkey but increased in incidence and severity at higher doses. Severe clinical signs in monkeys (emesis and diarrhea) necessitated the lowering of the top dose to 500 mg/kg/day (administered b.i.d.) during the second week of the monkey study. Slight decreases (< 23%) in serum protein and/or albumin were noted in all studies at the higher doses. A dose-related increase in alkaline phosphatase was noted in both dog studies, with no other drug-related effect on clinical pathology parameters. A gastric ulcer occurred in one rat administered 500 mg/kg CI-986 for 13 weeks. Gastrointestinal ulcers were not noted at any other dose in rats or at any dose in dogs or monkeys. A dose-related eosinophilia of glandular stomach submucosa was noted in rats after 2 and 13 weeks of drug administration but not in dogs or monkeys. In the 2-week rat study, mean combined sex plasma drug concentrations monitored 2 hr after dose on Day 14 were 0.59, 1.10, 2.64, and 3.43 micrograms/ml for the 50, 250, 750, and 1,500 mg/kg dose groups, respectively. In the 2-week dog studies, maximum plasma drug concentrations on Day 10 or Day 11 were achieved within 2 hr of dose with mean combined sex Cmax values of 0.73, 2.05, and 2.62 micrograms/ml for the 50, 250, and 750 mg/kg groups, respectively. Hepatic microsomal induction characterized by increased microsomal protein, increased microsomal cytochrome P450 content, and increased p-nitroanisole O-demethylation activity was noted in dogs and monkeys but not rats. CI-986 was well tolerated in rats and dogs at the doses employed and in monkeys at doses up to 500 mg/kg (b.i.d.).(ABSTRACT TRUNCATED AT 250 WORDS)
CI-986(5-[3,5-双(1,1-二甲基乙基)-4-羟基苯基]-1,3,4-噻二唑-2(3H)-硫酮-2-羟基-N,N,N-三甲基乙铵盐)是一种新型抗炎化合物,属于环氧化酶和5-脂氧合酶的双重抑制剂。已开展研究以表征该化合物的临床前毒理学特性。CI-986分别以0、50、250、750和1500mg/kg的剂量给予大鼠2周或13周,以0、50、150和500mg/kg的剂量给予犬2周或13周,以0、50、250和1000mg/kg的剂量给予猴2周。未出现与药物相关的死亡。给予250mg/kg及以上剂量的大鼠出现轻微的毒性临床体征。犬和猴低剂量时未出现与药物相关的呕吐和腹泻,但高剂量时其发生率和严重程度增加。猴研究的第二周,猴出现的严重临床体征(呕吐和腹泻)使得最高剂量降至500mg/kg/天(每日两次给药)。所有研究中,高剂量时血清蛋白和/或白蛋白均有轻微降低(<23%)。两项犬研究均发现碱性磷酸酶随剂量增加,且未发现对临床病理参数有其他与药物相关的影响。一只给予500mg/kg CI-986达13周的大鼠出现胃溃疡。大鼠的其他剂量以及犬和猴的任何剂量均未发现胃肠道溃疡。给药2周和13周后,大鼠腺胃黏膜下层出现与剂量相关的嗜酸性粒细胞增多,但犬和猴未出现。在为期2周的大鼠研究中,第14天给药后2小时监测的平均两性血浆药物浓度,50、250、750和1500mg/kg剂量组分别为0.59、1.10、2.64和3.43μg/ml。在为期2周的犬研究中,第10天或第11天的最大血浆药物浓度在给药后2小时内达到,50、250和750mg/kg组的平均两性Cmax值分别为0.73、2.05和2.62μg/ml。犬和猴出现肝微粒体诱导,表现为微粒体蛋白增加、微粒体细胞色素P450含量增加以及对硝基苯甲醚O-脱甲基活性增加,但大鼠未出现。在所采用的剂量下,CI-986在大鼠和犬中耐受性良好,在猴中剂量高达500mg/kg(每日两次给药)时也耐受性良好。(摘要截短至250字)